Robert H. J. Hargreaves

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.

Shannon L. Winski, Robert H. J. Hargreaves, John Butler et al. · PubMed · 1998 · 111 citations

New Aziridinylbenzoquinone, Aldo-keto Reductase, H596 Nsclc +18

Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.

Howard D. Beall, A-M Murphy, David J. Siegel et al. · Molecular Pharmacology · 1995 · 96 citations

Structure-Based Development of Anticancer Drugs

M. Faig, Mario A. Bianchet, Shannon L. Winski et al. · Structure · 2001 · 84 citations · Full text

Medicinal Chemistry, Structure-based Development, Drug Design +8

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones 1 2 1In accordance with the policy of the University of Colorado Health Sciences Center, D.R., R.H.J.H., and J.B. declare a patent interest in RH1. 2Abbreviations: MMC, mitomycin C; NQO1, NAD(P)H:quinone oxidoreductase 1 or DT-diaphorase; MeDZQ, 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone; DCPIP, 2,6-dichlorophenol-indophenol; MTT, thiazolyl blue; P450R, NADPH:cytochrome P450 reductase; b5R, NADH:cytochrome b5 reductase; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; FBS, fetal bovine serum; and MEM, Eagle’s minimum essential medium.

Shannon L. Winski, Elizabeth Swann, Robert H. J. Hargreaves et al. · Biochemical Pharmacology · 2001 · 83 citations

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

Timothy H. Ward, Sarah Danson, Alan T. McGown et al. · Clinical Cancer Research · 2005 · 22 citations · Full text